NCT01879020View on ClinicalTrials.gov

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Dyslipidemia
Interventions
DRUG

TA-8995

Drug: TA-8995 1mg

DRUG

TA-8995

Drug: TA-8995 2.5mg

DRUG

TA-8995

Drug: TA-8995 5mg

DRUG

TA-8995

Drug: TA-8995 10mg

DRUG

TA-8995

Drug: TA-8995 25mg

DRUG

Placebo

Placebo (TA-8995 1mg)

DRUG

Placebo

Placebo (TA-8995 2.5mg)

DRUG

Placebo

Placebo (TA-8995 5mg)

DRUG

Placebo

Placebo (TA-8995 10mg)

DRUG

Placebo

Placebo (TA-8995 25mg)

Trial Locations (1)

22769

Momentum Pharma Services GmbH, Hamburg

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY